E. N. Koltsova
Research Subjects
E. N. Koltsova has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Galina V. Lukina
V.A. Nasonova Research Institute of Rheumatology
8 shared publications - E. I. Schmidt
City Clinical Hospital No. 1 named after N.I. Pirogov
5 shared publications - E. V. Zhilyayev
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
3 shared publications E. Zhilyaev
Russian Medical Academy of Continuing Professional Education, Rheumatology, Moscow, Russian Federation
3 shared publicationsK. Lytkina
City Clinical Hospital#4, Rheumatology department, Moscow, Russian Federation
3 shared publications- Alexander A. Novikov
A.S. Loginov Moscow Clinical Scientific Center
2 shared publications
Latest Publications
- 27 January 2026
- Published by Alfmed LLC in Medical alphabet
- Vol. 1 (34)
Inflammatory bowel disease-associated antibodies in ankylosing spondylitis: relationship with clinical and laboratory markers of inflammation
Background/Purpose. To study the relationship between levels of antibodies associated with inflammatory bowel diseases (IBD) and inflammatory markers in ankylosing spondylitis (AS). Materials and methods. The sera of 44 healthy donors (HD) and 51 patients with AS were studied: 40 men, 11 women aged 44.0 (34.0–49.0) years with a disease duration of 12.0 (5.0–20.0) years, high disease activity (BASDAI – 5.3; 4.5–6.4; ASDAS ESR – 3.6; 3.0–4.4; ASDAS CRP – 3.7; 2.8–4.5). IBD was diagnosed in 22 % of patients with AS. IgG/IgA antibodies to S. cerevisiae (ASCA), IgG/IgA antibodies to glycoprotein 2 (GP2), IgG antibodies to cathepsin G, elastase, serum calprotectin (sCP), interleukin-6 (IL-6) were determined by ELISA. Results. Patients with AS without IBD and AS with IBD had higher levels of IgA ASCA, IgA aGP2, and elastase antibodies than HD (4.5; 2.6–6.4 U/ml and 4.9; 3.7–7.3 U/ml vs 1.9; 0.6–2.6 U/ml, p=0.0008, p=0.001; 1.2; 0.8–5.5 U/ml and 1.2; 0.9–11.8 U/ml vs 0.7; p=0.007, p=0.02; 8.2; 5.9–9.9 U/ml and 9.1; 8.5–10.5 U/ml vs 5.6; 4.7–8.3 U/ml, p=0.01, p=0.003). The concentration of antibodies to cathepsin G was higher in AS with IBD compared to AS without IBD (0.8; 0.5–1.0 U/ml vs 0.4; 0.3–0.6 U/ml, p=0.02). The levels of IgA ASCA correlated with IL-6 (r=0.3), IgA aGP2 – with sCP (r=0.3), antibodies to elastase – with ESR (r=0.4), antibodies to cathepsin G – with ESR (r=0.4) and BASDAI (r=0.4) (pConclusion. Elevated levels of IgA ASCA, IgA aGP2, and anti-elastase antibodies in AS without IBD are similar to those in AS with IBD. Hyperproduction of IgA ASCA, IgA aGP2, anti-elastase antibodies, and cathepsin G reflects the inflammatory activity of AS.
- 27 January 2026
- Published by Alfmed LLC in Medical alphabet
- Vol. 1 (34)
Inflammatory bowel disease-associated antibodies in ankylosing spondylitis: relationship with clinical and laboratory markers of inflammation
Background/Purpose. To study the relationship between levels of antibodies associated with inflammatory bowel diseases (IBD) and inflammatory markers in ankylosing spondylitis (AS). Materials and methods. The sera of 44 healthy donors (HD) and 51 patients with AS were studied: 40 men, 11 women aged 44.0 (34.0–49.0) years with a disease duration of 12.0 (5.0–20.0) years, high disease activity (BASDAI – 5.3; 4.5–6.4; ASDAS ESR – 3.6; 3.0–4.4; ASDAS CRP – 3.7; 2.8–4.5). IBD was diagnosed in 22 % of patients with AS. IgG/IgA antibodies to S. cerevisiae (ASCA), IgG/IgA antibodies to glycoprotein 2 (GP2), IgG antibodies to cathepsin G, elastase, serum calprotectin (sCP), interleukin-6 (IL-6) were determined by ELISA. Results. Patients with AS without IBD and AS with IBD had higher levels of IgA ASCA, IgA aGP2, and elastase antibodies than HD (4.5; 2.6–6.4 U/ml and 4.9; 3.7–7.3 U/ml vs 1.9; 0.6–2.6 U/ml, p=0.0008, p=0.001; 1.2; 0.8–5.5 U/ml and 1.2; 0.9–11.8 U/ml vs 0.7; p=0.007, p=0.02; 8.2; 5.9–9.9 U/ml and 9.1; 8.5–10.5 U/ml vs 5.6; 4.7–8.3 U/ml, p=0.01, p=0.003). The concentration of antibodies to cathepsin G was higher in AS with IBD compared to AS without IBD (0.8; 0.5–1.0 U/ml vs 0.4; 0.3–0.6 U/ml, p=0.02). The levels of IgA ASCA correlated with IL-6 (r=0.3), IgA aGP2 – with sCP (r=0.3), antibodies to elastase – with ESR (r=0.4), antibodies to cathepsin G – with ESR (r=0.4) and BASDAI (r=0.4) (pConclusion. Elevated levels of IgA ASCA, IgA aGP2, and anti-elastase antibodies in AS without IBD are similar to those in AS with IBD. Hyperproduction of IgA ASCA, IgA aGP2, anti-elastase antibodies, and cathepsin G reflects the inflammatory activity of AS.
- 6 June 2025
- Published by Alfmed LLC in Medical alphabet
- No. 9,p. 11-16
Efficacy and safety of upadacitinib therapy in patients with rheumatoid arthritis in real-world clinical practice: 12-month follow-up results
Background/Purpose. Upadacitinib (UPA) is an oral Janus kinase inhibitor, which has selectivity of JAK1 over JAK2, JAK3, and tyrosine kinase 2. UPA demonstrated efficacy for the treatment of RA, with acceptable safety profiles. We analyzed efficacy and tolerability of UPA in small Russian cohort of patients with rheumatoid arthritis.Materials and methods. Patients (n=24) with high RA activity (DAS 28 5.1±1.1, SDAI 27,5±11,2, CDAI 24,5±9,7) and an inadequate response of synthetic DMARDs (mainly methotrexate, 71 %) and biologics (mainly TNF-α blockers, 24 %) were included in the study. The majority of patients were middle-aged (46,8±15,4), RF (88 %) and ACPA (84 %) positive, with moderate functional impairment – 1.6 (1.25–2). UPA were administered per os, 15 mg daily. The evaluation of the effectiveness of the therapy was carried out according to the EULAR/ACR 2011 criteria and using SDAI, CDAI.Results. UPA led to a significant (pConclusion. UPA has shown significant improvement clinical status in patients who had an inadequate response to previous therapy. UPA was well tolerated. AE were registered in a small number of patients.
- 6 June 2025
- Published by Alfmed LLC in Medical alphabet
- No. 9,p. 11-16
Efficacy and safety of upadacitinib therapy in patients with rheumatoid arthritis in real-world clinical practice: 12-month follow-up results
Background/Purpose. Upadacitinib (UPA) is an oral Janus kinase inhibitor, which has selectivity of JAK1 over JAK2, JAK3, and tyrosine kinase 2. UPA demonstrated efficacy for the treatment of RA, with acceptable safety profiles. We analyzed efficacy and tolerability of UPA in small Russian cohort of patients with rheumatoid arthritis.Materials and methods. Patients (n=24) with high RA activity (DAS 28 5.1±1.1, SDAI 27,5±11,2, CDAI 24,5±9,7) and an inadequate response of synthetic DMARDs (mainly methotrexate, 71 %) and biologics (mainly TNF-α blockers, 24 %) were included in the study. The majority of patients were middle-aged (46,8±15,4), RF (88 %) and ACPA (84 %) positive, with moderate functional impairment – 1.6 (1.25–2). UPA were administered per os, 15 mg daily. The evaluation of the effectiveness of the therapy was carried out according to the EULAR/ACR 2011 criteria and using SDAI, CDAI.Results. UPA led to a significant (pConclusion. UPA has shown significant improvement clinical status in patients who had an inadequate response to previous therapy. UPA was well tolerated. AE were registered in a small number of patients.
- Open Access
- 15 October 2024
- Published by Publishing House ABV Press in The Clinician
- Vol. 18 (4) , 27-36
Difficult-to-treat rheumatoid arthritis: predictors and prevention possibilities (analysis of the Moscow unified register of arthritis data)
Aim. To search for factors associated with the occurrence of a difficult-to-treat state, reflecting the characteristics of both the patient and his disease, as well as preceding treatment. Materials and methods. The analysis includes data of patients with rheumatoid arthritis (RA) from the Moscow Unified Arthritis Registry (MUAR). All included patients received вiological Disease-Modifying Antirheumatic Drugs (bDMARDs) and / or targeted synthetic DMARDs (tsDMARDs). Prior to this, all patients were treated with tsDMARDs. The group of difficult-to-treat patients included persons in whom attempts to treat bDMARDs / tsDMARDs with the first two classes of drugs were not successful, and attempts to use bDMARDs / tsDMARDs were continued. Patients in whom an attempt to treat bDMARDs / tsDMARDs of the first or second class proved effective and treatment with the appropriate drug lasted at least 2 years are not difficult-to-treat. All other cases were excluded from the analysis. The differences between the two groups were studied according to various indicators, including demographic, anthropometric, indicators describing the features of the disease, clinical manifestations of the onset and further course of the disease. From the indicators that demonstrated significant differences between the groups, significant independent predictors of difficult-to-treatstate were identified within the linear-logistic regression model by forward stepwise selection. Data describing preceding treatment were analyzed within the framework of a multifactorial linear logistic model with included selected independent predictors of achieving difficult-to-treat state (resistance to treatment). Results. In the study were included 1044 patients, including 112 patients (10.7 %) were classified as difficult-to-treat. As significant independent predictors of treatment resistance, the following were identified: a patient’s message about an increase in body temperature at the onset of the disease of more than 38°C (p 0.001); a patient’s message about swelling of the hands during the disease (p = 0.033); the presence of rheumatoid nodules (p = 0.022); a relatively short time since the appearance of joint pain till contacting a doctor (p = 0.021). A significant relationship was found betweenbDMARD / tsDMARD used as first-line drug and the subsequent categorization of the patient as difficult-to-treat (p = 0.013). In patients receiving tofacitinib or rituximab in the first line of targeted therapy, the risk of subsequent treatment resistance was significantly lower than in patients receiving tumor necrosis factor inhibitors (iFNO): relative risk (RR) 0.017, 95 % confidence interval (CI) 0.04–0.72) and RR 0.47, 95 % CI 0.22–0.98), respectively. The analysis of the second line of targeted therapy revealed a significant advantage of etanercept over some other classes of bDMARDs / tsDMARDs in terms of the risk of subsequent treatment resistance. Thus, RR for other drugs of the iFNO class was 2.48 (95 % CI 1.13–5.44, p = 0.023); for abatacept – 3.15 (95 % CI 1.488–6.68, p = 0.003), and for tocilizumab – 2.57 (95 % CI 1.03–6.40; p = 0.043). Conclusion. The analysis of data from the registry of patients who were in real clinical practice made it possible to identify patients who accurately meet criteria of the European Alliance of Associations for Rheumatology for difficult-to-treat RA and patients who exactly do not meet them. A comparative analysis of the groups revealed predictors of following classifying the patient as difficult-to-treat. Based on the listed signs, high-risk groups of resistance to treatment with bDMARDs / tsDMARDs can be identified. The results obtained give grounds for the preferred use in such patients on the first line of treatment of tofacitinib or, possibly, other JAK kinase inhibitors, and on the second line of etanercept.
- 15 October 2024
- Published by Publishing House ABV Press in The Clinician
- Vol. 18 (4) , 27-36
Open AccessDifficult-to-treat rheumatoid arthritis: predictors and prevention possibilities (analysis of the Moscow unified register of arthritis data)
Aim. To search for factors associated with the occurrence of a difficult-to-treat state, reflecting the characteristics of both the patient and his disease, as well as preceding treatment. Materials and methods. The analysis includes data of patients with rheumatoid arthritis (RA) from the Moscow Unified Arthritis Registry (MUAR). All included patients received вiological Disease-Modifying Antirheumatic Drugs (bDMARDs) and / or targeted synthetic DMARDs (tsDMARDs). Prior to this, all patients were treated with tsDMARDs. The group of difficult-to-treat patients included persons in whom attempts to treat bDMARDs / tsDMARDs with the first two classes of drugs were not successful, and attempts to use bDMARDs / tsDMARDs were continued. Patients in whom an attempt to treat bDMARDs / tsDMARDs of the first or second class proved effective and treatment with the appropriate drug lasted at least 2 years are not difficult-to-treat. All other cases were excluded from the analysis. The differences between the two groups were studied according to various indicators, including demographic, anthropometric, indicators describing the features of the disease, clinical manifestations of the onset and further course of the disease. From the indicators that demonstrated significant differences between the groups, significant independent predictors of difficult-to-treatstate were identified within the linear-logistic regression model by forward stepwise selection. Data describing preceding treatment were analyzed within the framework of a multifactorial linear logistic model with included selected independent predictors of achieving difficult-to-treat state (resistance to treatment). Results. In the study were included 1044 patients, including 112 patients (10.7 %) were classified as difficult-to-treat. As significant independent predictors of treatment resistance, the following were identified: a patient’s message about an increase in body temperature at the onset of the disease of more than 38°C (p 0.001); a patient’s message about swelling of the hands during the disease (p = 0.033); the presence of rheumatoid nodules (p = 0.022); a relatively short time since the appearance of joint pain till contacting a doctor (p = 0.021). A significant relationship was found betweenbDMARD / tsDMARD used as first-line drug and the subsequent categorization of the patient as difficult-to-treat (p = 0.013). In patients receiving tofacitinib or rituximab in the first line of targeted therapy, the risk of subsequent treatment resistance was significantly lower than in patients receiving tumor necrosis factor inhibitors (iFNO): relative risk (RR) 0.017, 95 % confidence interval (CI) 0.04–0.72) and RR 0.47, 95 % CI 0.22–0.98), respectively. The analysis of the second line of targeted therapy revealed a significant advantage of etanercept over some other classes of bDMARDs / tsDMARDs in terms of the risk of subsequent treatment resistance. Thus, RR for other drugs of the iFNO class was 2.48 (95 % CI 1.13–5.44, p = 0.023); for abatacept – 3.15 (95 % CI 1.488–6.68, p = 0.003), and for tocilizumab – 2.57 (95 % CI 1.03–6.40; p = 0.043). Conclusion. The analysis of data from the registry of patients who were in real clinical practice made it possible to identify patients who accurately meet criteria of the European Alliance of Associations for Rheumatology for difficult-to-treat RA and patients who exactly do not meet them. A comparative analysis of the groups revealed predictors of following classifying the patient as difficult-to-treat. Based on the listed signs, high-risk groups of resistance to treatment with bDMARDs / tsDMARDs can be identified. The results obtained give grounds for the preferred use in such patients on the first line of treatment of tofacitinib or, possibly, other JAK kinase inhibitors, and on the second line of etanercept.
- Open Access
- 3 March 2024
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (1) , 77-88
Immunogenicity and Safety of 13-valent Conjugated Pneumococcal Vaccine in Patients with Rheumatoid Arthritis
Иммуногенность и безопасность 13-валентной конъюгированной пневмококковой вакцины у больных ревматоидным артритом
- 3 March 2024
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (1) , 77-88
Open AccessImmunogenicity and Safety of 13-valent Conjugated Pneumococcal Vaccine in Patients with Rheumatoid Arthritis
Иммуногенность и безопасность 13-валентной конъюгированной пневмококковой вакцины у больных ревматоидным артритом
- Open Access
- 17 December 2022
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 16 (6) , 26-31
Predictors of biologic disease modifying antirheumatic drugs withdrawal due to the development of adverse events in patients with rheumatoid arthritis
Currently, a large number of highly effective biologic disease modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) are used for the treatment of rheumatoid arthritis (RA). However, in addition to effectiveness, it is necessary to evaluate the risk of adverse events (AEs) when using them.Objective: to determine the predictors of bDMARDs and tsDMARDs discontinuation due to AEs in patients with RA.Patients and methods. The study included 661 patients with RA who took bDMARDs and tsDMARDs. The search for predictors of targeted therapy discontinuation due to AEs was carried out in two stages. At the first stage, using the Kaplan-Meier method, we selected indicators that showed the greatest significant single-factor relationship with the duration of retention on therapy. At the second stage, significant independent indicators were obtained by iterative selection of variables within the multivariate proportional risk model according to Cox.Results and discussion. The presence of rheumatoid nodules (pConclusion. An increase in the dose of MT and decrease in the use of GCs can help prevent the development of AEs leading to the abolition of biologics and tsDMARDs. Significant differences were found between bDMARDs in terms of the risk of their cancellation due to AEs.
- 17 December 2022
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 16 (6) , 26-31
Open AccessPredictors of biologic disease modifying antirheumatic drugs withdrawal due to the development of adverse events in patients with rheumatoid arthritis
Currently, a large number of highly effective biologic disease modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) are used for the treatment of rheumatoid arthritis (RA). However, in addition to effectiveness, it is necessary to evaluate the risk of adverse events (AEs) when using them.Objective: to determine the predictors of bDMARDs and tsDMARDs discontinuation due to AEs in patients with RA.Patients and methods. The study included 661 patients with RA who took bDMARDs and tsDMARDs. The search for predictors of targeted therapy discontinuation due to AEs was carried out in two stages. At the first stage, using the Kaplan-Meier method, we selected indicators that showed the greatest significant single-factor relationship with the duration of retention on therapy. At the second stage, significant independent indicators were obtained by iterative selection of variables within the multivariate proportional risk model according to Cox.Results and discussion. The presence of rheumatoid nodules (pConclusion. An increase in the dose of MT and decrease in the use of GCs can help prevent the development of AEs leading to the abolition of biologics and tsDMARDs. Significant differences were found between bDMARDs in terms of the risk of their cancellation due to AEs.
- Open Access
- 6 September 2021
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 59 (4) , 394–400
Evaluation of the effectiveness of Tofacitinib in rheumatoid arthritis in real clinical practice: The relationship between pain relief in the first 4 weeks and disease activity after 3–6 months
The JAK inhibitor tofacitinib (TOFA) blocks the intracellular signaling pathway that activates the synthesis of cytokines and mediators involved in the development of pain and central sensitization (CS), which determines the rapid analgesic effect. However, it is not clear how pain reduction is associated with achieving low activity in rheumatoid arthritis (RA).The aim of the studywas to assess the relationship between the early clinical response to tofacitinib and a decrease in rheumatoid arthritis activity after 3 and 6 months.Material and methods.The study group consisted of 88 RA patients (age – 53±11.5 years; 79.3% of women) who received basic anti-inflammatory drugs (59.5% – methotrexate, 19.8% – leflunomide) and who were prescribed TOFA in a dose 10 mg/day. Seropositivity for rheumatoid factor was 89.8%; the value of the DAS28 index is 5.2±1.2. The severity of pain was assessed using the Brief Pain Inventory questionnaire, the neuropathic component of pain (NCP) – using the PainDETECT questionnaire, signs of CS – using the Central Sensitization Inventory (CSI) questionnaire in the early stages after the administration of TOFA, RA activity – using the DAS28-CRP index after 3 and 6 months.Results.The mean severity of pain at baseline was 5.3±2.0 on the visual analogue scale (VAS); 51.1% of patients had signs of CS (CSI>40), 15.9% had NCP (PainDETECT>18). 7 days after the start of therapy, there was a significant decrease in pain – to 4.1±1.8 according to VAS (pConclusions.The use of the JAK inhibitor TOFA allows achieving a quick analgesic effect and reducing the signs of CS. An early clinical response to TOFA (pain relief) predicts a decrease in RA activity after 3 and 6 months of therapy.
- 6 September 2021
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 59 (4) , 394–400
Open AccessEvaluation of the effectiveness of Tofacitinib in rheumatoid arthritis in real clinical practice: The relationship between pain relief in the first 4 weeks and disease activity after 3–6 months
The JAK inhibitor tofacitinib (TOFA) blocks the intracellular signaling pathway that activates the synthesis of cytokines and mediators involved in the development of pain and central sensitization (CS), which determines the rapid analgesic effect. However, it is not clear how pain reduction is associated with achieving low activity in rheumatoid arthritis (RA).The aim of the studywas to assess the relationship between the early clinical response to tofacitinib and a decrease in rheumatoid arthritis activity after 3 and 6 months.Material and methods.The study group consisted of 88 RA patients (age – 53±11.5 years; 79.3% of women) who received basic anti-inflammatory drugs (59.5% – methotrexate, 19.8% – leflunomide) and who were prescribed TOFA in a dose 10 mg/day. Seropositivity for rheumatoid factor was 89.8%; the value of the DAS28 index is 5.2±1.2. The severity of pain was assessed using the Brief Pain Inventory questionnaire, the neuropathic component of pain (NCP) – using the PainDETECT questionnaire, signs of CS – using the Central Sensitization Inventory (CSI) questionnaire in the early stages after the administration of TOFA, RA activity – using the DAS28-CRP index after 3 and 6 months.Results.The mean severity of pain at baseline was 5.3±2.0 on the visual analogue scale (VAS); 51.1% of patients had signs of CS (CSI>40), 15.9% had NCP (PainDETECT>18). 7 days after the start of therapy, there was a significant decrease in pain – to 4.1±1.8 according to VAS (pConclusions.The use of the JAK inhibitor TOFA allows achieving a quick analgesic effect and reducing the signs of CS. An early clinical response to TOFA (pain relief) predicts a decrease in RA activity after 3 and 6 months of therapy.
- Open Access
- 1 June 2021
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 80 (Suppl 1) , 1265
AB0475 COMPARATIVE EFFECTIVENESS OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN REAL CLINICAL PRACTICE ACCORDING TO THE MOSCOW UNIFIED ARTHRITIS REGISTER (MUAR)
Background: This study is the first analysis of biological disease-modifying antirheumatic drugs (bDMARDs) for ankylosing spondylitis (AS) within the Moscow Unified Arthritis Register (MUAR). Objectives: to compare the effectiveness of bDMARDs in patients with AS using data from the MUAR. Methods: The analysis included the data of patients with AS who were included in the MUAR and received biological therapy for at least 6 months. The effectiveness of the drugs was assessed by the achieved values of the indices of diseases activity and its manifestations: ASDAS(C-RP), BASDAI, LEI, MASES, indicators of the functional ability of patients (BASFI, HAQ) at the last completed visit. Comparison of indicators between drugs was in a general linear model, adjusted for the identified confounders. The search for confounders was in 2 stages: first, by univariate analysis, were identified indicators significantly related to the achieved ASDAS. Then, within the multivariate general linear model, by backward stepwise selection were determinate variables significantly and independently associated with ASDAS. Results: The current study included 363 episodes of treatment with bDMARDs in 361 patients. There were 240 men (66.5%). The average age of the included patients was 46.3 ± 11.2, the age at the onset of the disease was 27.3 ± 11.4. The average duration of a treatment episode until the patient was assessed 1135 ± 900 days. Significant differences of the values of ASDAS(p = 0.033) and ESR (p = 0.007) between bDMARDs were revealed. In pairwise comparisons of the achieved ASDAS using the Shidak adjustment, demonstrated that the values on infliximab and adalimumab were significantly lower than on certolizumab pegol (p = 0.009 and p = 0.041, respectively). Also significantly higher ESR values on certolizumab compared to all other drugs (p < 0.001 for all) were found. There were no statistically significant differences between the drugs for other studied parameters. Conclusion: The studied bDMARDs (infliximab, adalimumab, etanercept, certolizumab pegol, golimumab, secukinumab) demonstrate generally similar clinical efficacy in real clinical practice. The effect of golimumab and sekukinumab which have been recently introduced into clinical practice doesn’t differ significantly from the effect of TNF inhibitors which has been used for a long time. Achieved values of the indices of activity and functional ability against the background of treatment with bDMARDs. Disclosure of Interests: None declared.
- 1 June 2021
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 80 (Suppl 1) , 1265
Open AccessAB0475 COMPARATIVE EFFECTIVENESS OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN REAL CLINICAL PRACTICE ACCORDING TO THE MOSCOW UNIFIED ARTHRITIS REGISTER (MUAR)
Background: This study is the first analysis of biological disease-modifying antirheumatic drugs (bDMARDs) for ankylosing spondylitis (AS) within the Moscow Unified Arthritis Register (MUAR). Objectives: to compare the effectiveness of bDMARDs in patients with AS using data from the MUAR. Methods: The analysis included the data of patients with AS who were included in the MUAR and received biological therapy for at least 6 months. The effectiveness of the drugs was assessed by the achieved values of the indices of diseases activity and its manifestations: ASDAS(C-RP), BASDAI, LEI, MASES, indicators of the functional ability of patients (BASFI, HAQ) at the last completed visit. Comparison of indicators between drugs was in a general linear model, adjusted for the identified confounders. The search for confounders was in 2 stages: first, by univariate analysis, were identified indicators significantly related to the achieved ASDAS. Then, within the multivariate general linear model, by backward stepwise selection were determinate variables significantly and independently associated with ASDAS. Results: The current study included 363 episodes of treatment with bDMARDs in 361 patients. There were 240 men (66.5%). The average age of the included patients was 46.3 ± 11.2, the age at the onset of the disease was 27.3 ± 11.4. The average duration of a treatment episode until the patient was assessed 1135 ± 900 days. Significant differences of the values of ASDAS(p = 0.033) and ESR (p = 0.007) between bDMARDs were revealed. In pairwise comparisons of the achieved ASDAS using the Shidak adjustment, demonstrated that the values on infliximab and adalimumab were significantly lower than on certolizumab pegol (p = 0.009 and p = 0.041, respectively). Also significantly higher ESR values on certolizumab compared to all other drugs (p < 0.001 for all) were found. There were no statistically significant differences between the drugs for other studied parameters. Conclusion: The studied bDMARDs (infliximab, adalimumab, etanercept, certolizumab pegol, golimumab, secukinumab) demonstrate generally similar clinical efficacy in real clinical practice. The effect of golimumab and sekukinumab which have been recently introduced into clinical practice doesn’t differ significantly from the effect of TNF inhibitors which has been used for a long time. Achieved values of the indices of activity and functional ability against the background of treatment with bDMARDs. Disclosure of Interests: None declared.
- Open Access
- 1 June 2021
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 80 (Suppl 1) , 731-732
POS0937 TREATMENT SURVIVAL ON BIOLOGICS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS – DATA FROM MOSCOW UNIFIED ARTHRITIS REGISTRY (MUAR)
Background: The number of new biologics in treatment of axial spondyloarthritis (axSpA) is rapidly increasing. It is important to assess timely their place in the treatment of axSpA, especially with regard to retention on therapy. Objectives: To compare retention on therapy with different biologics in patients with axSpA. Methods: We retrospectively analyzed the data of axSpA patients receiving biologics from the MUAR register. Predictors of retention on therapy were selected by forward stepwise variable selection within Cox regression proportional hazard model. These predictors were considered as confounders when comparing the risks of biologics withdrawal. Results: 990 treatment episodes in 640 patients with axSpA were analyzed (non-radiographic axSpA – 4.1%, ankylosing spondylitis - 95.9%). The duration of episodes was 824±920 days. Men were 66,6%, mean age 46,4±11,4.The patients were treated with Adalimumab (ADA) (n= 252 treatment episodes), Golimumab (GOL) (n=82), Infliximab (INF) (n=167), Netakimab (NET) (n=9), Secukinumab (SEC) (n=75), Certolizumab pegol (CER) (n=66), Etanercept (ETA) (n=339). The following predictors of withdrawal risk were identified – 1.The total duration of the disease 2.The duration of the disease before the onset of biologic treatment 3.Gender 4.Family history of non-inflammatory spondylopathy (degenerative spinal disease) 5.The line of biologic treatment 6.The level of education The severity of radiographic sacroiliitis and HLA B-27 positivity were not associated with the risk of discontinuation of biologics. The identified predictors were further considered as confounders. Adjusted for confounders, ETA had the lowest treatment withdrawal risk (Figure 1). ADA, GOL, INF, SEC, CER had significantly higher risk of withdrawal compared with ETA (Table 1). Conclusion: Our analysis detected predictors associated with risk of biologics withdrawal in axSpA patients in real clinical practice. There are significant differences between biologics regarding retention on treatment. Hazard ratio for treatment withdrawal Picture 1. Treatment withdrawal risk Disclosure of Interests: None declared
- 1 June 2021
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 80 (Suppl 1) , 731-732
Open AccessPOS0937 TREATMENT SURVIVAL ON BIOLOGICS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS – DATA FROM MOSCOW UNIFIED ARTHRITIS REGISTRY (MUAR)
Background: The number of new biologics in treatment of axial spondyloarthritis (axSpA) is rapidly increasing. It is important to assess timely their place in the treatment of axSpA, especially with regard to retention on therapy. Objectives: To compare retention on therapy with different biologics in patients with axSpA. Methods: We retrospectively analyzed the data of axSpA patients receiving biologics from the MUAR register. Predictors of retention on therapy were selected by forward stepwise variable selection within Cox regression proportional hazard model. These predictors were considered as confounders when comparing the risks of biologics withdrawal. Results: 990 treatment episodes in 640 patients with axSpA were analyzed (non-radiographic axSpA – 4.1%, ankylosing spondylitis - 95.9%). The duration of episodes was 824±920 days. Men were 66,6%, mean age 46,4±11,4.The patients were treated with Adalimumab (ADA) (n= 252 treatment episodes), Golimumab (GOL) (n=82), Infliximab (INF) (n=167), Netakimab (NET) (n=9), Secukinumab (SEC) (n=75), Certolizumab pegol (CER) (n=66), Etanercept (ETA) (n=339). The following predictors of withdrawal risk were identified – 1.The total duration of the disease 2.The duration of the disease before the onset of biologic treatment 3.Gender 4.Family history of non-inflammatory spondylopathy (degenerative spinal disease) 5.The line of biologic treatment 6.The level of education The severity of radiographic sacroiliitis and HLA B-27 positivity were not associated with the risk of discontinuation of biologics. The identified predictors were further considered as confounders. Adjusted for confounders, ETA had the lowest treatment withdrawal risk (Figure 1). ADA, GOL, INF, SEC, CER had significantly higher risk of withdrawal compared with ETA (Table 1). Conclusion: Our analysis detected predictors associated with risk of biologics withdrawal in axSpA patients in real clinical practice. There are significant differences between biologics regarding retention on treatment. Hazard ratio for treatment withdrawal Picture 1. Treatment withdrawal risk Disclosure of Interests: None declared
- Open Access
- 1 June 2020
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (Suppl 1) , 1451
AB0303 PREDICTORS OF SERIOUS INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TARGET THERAPY.
Background: The problem of infectious complications in patients receiving bDMARDs deserves special attention. Serious infectious adverse events (SIAE) are a most important issue. To develop measures for their prevention it is necessary to know the predisposing factors. Objectives: to detect predictors of serious infections among patients with rheumatoid arthritis receiving targeted therapy Methods: The study includes patients with rheumatoid arthritis from the Moscow Unified Arthritis Registry (MUAR), receiving treatment with biologics or tofacitinib. Search for predictors was carried out in two steps. At first step we selected patient related predictors (confounders) that significantly correlate with risk of SIAE. At the second step in the Cox risk regression model by forward stepwise selection were identified independent significant predictors of risk. which demonstrated significant correlation with development of serious infections. Then data about the treatment was added to the generated model: used targeted DMARDs, doses of glucocorticoids (GC), doses of methotrexate (MTX). Results: Analysis includes 1052 treatment events in 772 patients. There were 44 serious infections. The mean age was 57,1 ± 12,8 years. The mean observation time – 5.3 years. Independent patient related predictors of SIAE risk were the age RR - 1.12 per year (CI: 1.06-1.19), the age of onset disease RR - 0.94 per year (CI: 0.90-0.98), the year of inclusion in the registry RR - 0.64 per year (CI: 0.49-0.85). The dose of MTX and the doses of GC positively correlate with SIAE risk. RR for MTX is 1.05 per mg (CI: 1.005-1.109), RR for GC - 1.11 per mg (CI: 1.004-1.236). Used targeted DMARD didn’t show any significant correlation with SIAE risk. Conclusion: Higher doses of methotrexate and glucocorticoids are independent significant predictors of serious infections in RA patients receiving targeted DMARDs. Disclosure of Interests: Ekaterina Koltsova: None declared, Galina Lukina Speakers bureau: Novartis, Pfizer, UCB, Abbvie, Biocad, MSD, Roche, Evgeniya Shmidt Speakers bureau: MSD, Novartis, Pfizer, Karine Lytkina Speakers bureau: Novartis, Eli Lilly, Pfizer, UCB, Abbvie, Biocad, MSD, Jonson&Jonson, Evgeniy Zhilyaev Speakers bureau: Novartis, UCB, Pfizer, Biocad, Abbvie, MSD, Roche
- 1 June 2020
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (Suppl 1) , 1451
Open AccessAB0303 PREDICTORS OF SERIOUS INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TARGET THERAPY.
Background: The problem of infectious complications in patients receiving bDMARDs deserves special attention. Serious infectious adverse events (SIAE) are a most important issue. To develop measures for their prevention it is necessary to know the predisposing factors. Objectives: to detect predictors of serious infections among patients with rheumatoid arthritis receiving targeted therapy Methods: The study includes patients with rheumatoid arthritis from the Moscow Unified Arthritis Registry (MUAR), receiving treatment with biologics or tofacitinib. Search for predictors was carried out in two steps. At first step we selected patient related predictors (confounders) that significantly correlate with risk of SIAE. At the second step in the Cox risk regression model by forward stepwise selection were identified independent significant predictors of risk. which demonstrated significant correlation with development of serious infections. Then data about the treatment was added to the generated model: used targeted DMARDs, doses of glucocorticoids (GC), doses of methotrexate (MTX). Results: Analysis includes 1052 treatment events in 772 patients. There were 44 serious infections. The mean age was 57,1 ± 12,8 years. The mean observation time – 5.3 years. Independent patient related predictors of SIAE risk were the age RR - 1.12 per year (CI: 1.06-1.19), the age of onset disease RR - 0.94 per year (CI: 0.90-0.98), the year of inclusion in the registry RR - 0.64 per year (CI: 0.49-0.85). The dose of MTX and the doses of GC positively correlate with SIAE risk. RR for MTX is 1.05 per mg (CI: 1.005-1.109), RR for GC - 1.11 per mg (CI: 1.004-1.236). Used targeted DMARD didn’t show any significant correlation with SIAE risk. Conclusion: Higher doses of methotrexate and glucocorticoids are independent significant predictors of serious infections in RA patients receiving targeted DMARDs. Disclosure of Interests: Ekaterina Koltsova: None declared, Galina Lukina Speakers bureau: Novartis, Pfizer, UCB, Abbvie, Biocad, MSD, Roche, Evgeniya Shmidt Speakers bureau: MSD, Novartis, Pfizer, Karine Lytkina Speakers bureau: Novartis, Eli Lilly, Pfizer, UCB, Abbvie, Biocad, MSD, Jonson&Jonson, Evgeniy Zhilyaev Speakers bureau: Novartis, UCB, Pfizer, Biocad, Abbvie, MSD, Roche